文献速递肿瘤 PET/CT放射性药物与辐射防护

重复早期68Ga-FAPI PET采集比较68Ga-FAPI-02、68Ga-FAPI-46与68Ga-FAPI-74:对恶性、炎症/反应性和退行性病变的方法学与诊断意义

Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions.
PubMed 文献 · J Nucl Med · 2022-05-26

该回顾性分析对24例癌症患者行全身PET,于注射150-250 MBq的68Ga-FAPI-02、-46或-74后10、22、34、46、58分钟重复采集,分析134个恶性、炎症/反应性和退行性病变的检出率与SUV。三种示踪剂在恶性及炎症/反应性病变的摄取均高于退行性病变,68Ga-FAPI-46摄取和靶本比最高;作者认为重复早期采集对鉴别良恶性有附加诊断价值,注射后30-40分钟采集是兼顾临床可行性的合理折中。

要点

  • 除脂肪和椎管外,多数健康组织摄取随时间下降。
  • 三种示踪剂在恶性及炎症/反应性病变的摄取均高于退行性病变。
  • 68Ga-FAPI-46在所有病变中摄取和靶本比最高。

核心结论

  • 68Ga-FAPI PET/CT是用于恶性肿瘤和良性病变的有前景的影像方法。
  • 重复早期PET采集为鉴别恶性和非恶性68Ga-FAPI阳性病变增加了诊断价值。
  • 高检出率和靶本比随时间维持证实注射后60分钟内采集可获得高对比图像;考虑临床可行性,注射后30-40分钟采集可能是合理的折中。
  • 不同68Ga-FAPI变体的时间依赖性生物分布行为存在显著差异,应根据临床场景仔细选择。

研究设计与样本

  • 回顾性分析纳入24例癌症患者,每种68Ga-FAPI示踪剂各8例,注射150-250 MBq后于10、22、34、46、58分钟行全身PET采集。
  • 测量健康组织、癌症表现和非恶性病变的检出率及SUVmax、SUVmean,并计算各时间点对血液和脂肪的靶本比。
  • 分析134个恶性、炎症/反应性和退行性病变。

主要发现

  • 除脂肪和椎管外,大多数健康组织的生物分布分析显示摄取随时间下降。
  • 检出率在最初2个采集时间点轻度降低,注射后34至58分钟维持在恒定高水平。
  • 三种变体在恶性及炎症/反应性病变中的摄取均高于退行性病变。
  • 68Ga-FAPI-46在所有病变中显示最高的摄取和靶本比。
  • 所有变体对各病变类型对血液的靶本比随时间持续升高,对脂肪的靶本比保持恒定或轻度下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-labeled fibroblast activation protein (FAP) inhibitor (68Ga-FAPI) PET targets 68Ga-FAPI-positive activated fibroblasts and is a promising imaging technique for various types of cancer and nonmalignant pathologies. However, discrimination between malignant and nonmalignant 68Ga-FAPI-positive lesions based on static PET with a single acquisition time point can be challenging. Additionally, the optimal imaging time point for 68Ga-FAPI PET has not been identified yet, and different 68Ga-FAPI tracer variants are currently used. In this retrospective analysis, we evaluate the diagnostic value of repetitive early 68Ga-FAPI PET with 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74 for malignant, inflammatory/reactive, and degenerative lesions and describe the implications for future 68Ga-FAPI imaging protocols. Methods: Whole-body PET scans of 24 cancer patients were acquired at 10, 22, 34, 46, and 58 min after the administration of 150-250 MBq of 68Ga-FAPI tracer molecules (8 patients each for 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74). Detection rates and SUVs (SUVmax and SUVmean) for healthy tissues, cancer manifestations, and nonmalignant lesions were measured, and target-to-background ratios (TBR) versus blood and fat were calculated for all acquisition time points. Results: For most healthy tissues except fat and spinal canal, biodistribution analysis showed decreasing uptake over time. We analyzed 134 malignant, inflammatory/reactive, and degenerative lesions. Detection rates were minimally reduced for the first 2 acquisition time points and remained at a constant high level from 34 to 58 min after injection. The uptake of all 3 variants was higher in malignant and inflammatory/reactive lesions than in degenerative lesions. 68Ga-FAPI-46 showed the highest uptake and TBRs in all pathologies. For all variants, TBRs versus blood constantly increased over time for all pathologies, and TBRs versus fat were constant or decreased slightly. Conclusion: 68Ga-FAPI PET/CT is a promising imaging modality for malignancies and benign lesions. Repetitive early PET acquisition added diagnostic value for the discrimination of malignant from nonmalignant 68Ga-FAPI-positive lesions. High detection rates and TBRs over time confirmed that PET acquisition earlier than 60 min after injection delivers high-contrast images. Additionally, considering clinical feasibility, acquisition at 30-40 min after injection might be a reasonable compromise. Different 68Ga-FAPI variants show significant differences in time-dependent biodistributional behavior and should be selected carefully depending on the clinical setting.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Glatting FM, Hoppner J, Liew DP, et al. Repetitive Early 68Ga-FAPI PET Acquisition Comparing 68Ga-FAPI-02, 68Ga-FAPI-46, and 68Ga-FAPI-74: Methodologic and Diagnostic Implications for Malignant, Inflammatory/Reactive, and Degenerative Lesions. J Nucl Med. 2022. PMID: 35618480. doi:10.2967/jnumed.122.264069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。